TREATMENT OF EQUINE LAMINITIS WITH 5-HT1B/ 1D ANTAGONISTS

摘要

There is provided the use of a compound of general formula (I): in which: R¹ represents hydrogen, halogen, C_1-6 alkyl, C_3-6 cycloalkyl, C_3-6 cycloalkenyl, C_1-6 alkoxy, hydroxy C_1-6 alkyl, C_1-6alkylOC_1-6 alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO₂R²⁹, CONR³⁰ R³¹ or NR³⁰R³¹; R² represents a phenyl group, having phenyl ring B, substituted by a group selected from i) a 5 to 7 membered heterocyclic ring containing three heteroatoms selected from oxygen, nitrogen or sulphur, optionally substituted by a substituent selected from halogen, C_1-6 alkyl, C_3-6 cycloalkyl, C_3-6 cycloalkenyl, C_1-6 alkoxy, hydroxy C_1-6 alkyl, C_1-6 alkyl OC_1-6 alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO₂R²⁹, CONR³⁰ R³¹ NR³⁰ R³¹, or NR³⁰R³¹, formula (ii): or formula (iii): and optionally further substituted by one or two auxiliary substituents selected from a halogen atom, a hydroxy group, a C_1-6 alkyl group, or by an auxiliary substituent selected from C_3-6 cycloalkyl, C_3-6 cycloalkenyl, hydroxy C_1-6 alkyl, C_1-6 alkylOC_1-6alkyl, acyl, aryl, acyloxy, nitro, trifluoromethyl, cyano, CO₂2R²⁹, CONR³⁰ R³¹, or NR³⁰ R³¹; D is CONH or NHCO; E is formula (A): or G-(CR²⁴ R²⁵)-NR²⁷R²⁸ where R⁵ represents a hydrogen atom or a C_1-6 alkyl group, G is oxygen, S(O)_p where p is 0, 1, or 2, NR³² where R³² is hydrogen, C_1-6 alkyl or phenyl C_1-6 alkyl, or G is CR²⁴ = CR²⁵ or CR²⁴ R²⁵ where R²⁴ and R²⁵ are independently hydrogen or C_1-6 alkyl; F is hydrogen, a halogen atom, a hydroxy group, a C1-6 alkoxy group, a C_1-6 alkyl group or a halogenated C_1-6 alkyl group; R²⁷ and R²⁸ are independently hydrogen, C_1-6 alkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5-to 7-membered heterocyclic ring containing one or two heteroatoms selected from oxygen, nitrogen or sulphur; R²⁹, R³⁰ and R³¹ are independently hydrogen or C_1-6 alkyl; m is 1 to 4; and n is 1 or 2 or a physiologically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment or prophylaxis of laminitis.